(Z)-4-(methylamino)-2-[2-(methylamino)-2-oxoethyl]-4-oxobut-2-enoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Z)-4-(methylamino)-2-[2-(methylamino)-2-oxoethyl]-4-oxobut-2-enoic acid
• 化学式: C₈H₁₂N₂O₄
• 分子量: 200.19
• InChiKey: MSVBQCRZPFWWMY-HYXAFXHYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  95.5
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• COMPOUND HAVING SUBSTANCE THAT HAS AFFINITY FOR SOLUBLE PROTEIN, CLEAVABLE MOIETY, AND REACTIVE GROUP, OR SALT THEREOF
  申请人：Ajinomoto Co., Inc.

  公开号：EP3617235A1

  公开（公告）日：2020-03-04

  The present invention provides a technique enabling modification of a soluble protein and in particular regioselective modification of a soluble protein. More specifically, the present invention provides a compound having an affinity substance to a soluble protein, a cleavable portion, and a reactive group represented by the following Formula (I):         A-L-B-R     (I) wherein A is an affinity substance to a soluble protein; L is a cleavable linker which is a divalent group comprising a cleavable portion; B is (a) a divalent group comprising a bioorthogonal functional group or (b) a divalent group comprising no bioorthogonal functional group; and R is a reactive group to the soluble protein; or a salt thereof.

  本发明提供了一种对可溶性蛋白质进行修饰的技术，特别是对可溶性蛋白质进行区域选择性修饰的技术。更具体地说，本发明提供了一种化合物，该化合物具有与可溶性蛋白质的亲和物质、可裂解部分和由下式（I）代表的活性基团： A-L-B-R (I) 其中 A 是与可溶性蛋白质亲和的物质； L 是可裂解连接体，是由可裂解部分组成的二价基团； B 是(a)包含生物正交官能团的二价基团或(b)不包含生物正交官能团的二价基团；以及 R 是可溶性蛋白质的活性基团；或 其盐。
• Targeted Therapeutic Nanoparticles
  申请人：nanoDERM Sciences, Inc.

  公开号：US20140199232A1

  公开（公告）日：2014-07-17

  Disclosure of methods and compositions related to chemical conjugations to nanoparticles of polysaccharides cross-linked to poloxamers as well as nano-sized colloids comprised of polysaccharides and poloxamers. The nanoparticles may be produced by various methods including inverse miniemulsion polymerization processes which create nanogels of desired size, shape, and stability for controlled therapeutic drug delivery, imaging, and theragnostic applications.
• TARGETED THERAPEUTIC NANOPARTICLES
  申请人：nanoDERM SCIENCES, INC.

  公开号：US20160106852A1

  公开（公告）日：2016-04-21

  Disclosure of methods and compositions related to chemical conjugations to nanoparticles of polysaccharides cross-linked to poloxamers as well as nano-sized colloids comprised of polysaccharides and poloxamers. The nanoparticles may be produced by various methods including inverse miniemulsion polymerization processes which create nanogels of desired size, shape, and stability for controlled therapeutic drug delivery, imaging, and theragnostic applications.
• DIMERIZER COMPOUND
  申请人：AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

  公开号：US20160297820A1

  公开（公告）日：2016-10-13

  There is provided a compound comprising at least two ligands that are individually coupled to a linker, wherein each ligand is independently selected from the group consisting of a substituted benzylguanine derivative, a substituted benzylcytosine derivative, a haloalkyl moiety, a drug, a peptide, a hormone, an inorganic compound and a protein. The compound may be part of an oligomer. The compound may be employed in a method of dimerizing a pair of proteins, which may alter a biological function in a cell. There is also provided a method of forming the compound.
• COMPOUND HAVING AFFINITY SUBSTANCE TO SOLUBLE PROTEIN, CLEAVABLE PORTION AND REACTIVE GROUP, OR SALT THEREOF
  申请人：Ajinomoto Co., Inc.

  公开号：US20200190165A1

  公开（公告）日：2020-06-18

  The present invention provides a technique enabling modification of a soluble protein and in particular regioselective modification of a soluble protein. More specifically, the present invention provides a compound having an affinity substance to a soluble protein, a cleavable portion, and a reactive group represented by the following Formula (I): A-L-B-R  (I) wherein A is an affinity substance to a soluble protein; L is a cleavable linker which is a divalent group comprising a cleavable portion; B is (a) a divalent group comprising a bioorthogonal functional group or (b) a divalent group comprising no bioorthogonal functional group; and R is a reactive group to the soluble protein; or a salt thereof.